Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIUS19KTN)
  Drug Name Norepinephrine Drug Info Orciprenaline Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Vasoconstrictor Agents Adrenergic Bronchodilators
  Structure

 Mechanism of Norepinephrine-Orciprenaline Interaction (Severity Level: Moderate)
     Additive hypertensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Norepinephrine Orciprenaline
      Mechanism 1 Hypertensive effects Hypertensive effects
      Key Mechanism Factor 1
Factor Name Hypertensive effects
Factor Description Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head.
      Mechanism Description
  • Additive hypertensive effects by the combination of Norepinephrine and Orciprenaline 
     Increased risk of rapid heart rate Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Norepinephrine Orciprenaline
      Mechanism 2 Tachycardia Tachycardia
      Key Mechanism Factor 2
Factor Name Tachycardia
Factor Description A faster-than-normal heart rate, but the heart is beating normally. Tachycardia may not cause any symptoms or complications, but if left untreated, some forms of tachycardia can lead to serious health problems, including heart failure, stroke, or sudden cardiac death.
      Mechanism Description
  • Increased risk of rapid heart rate by the combination of Norepinephrine and Orciprenaline 

Recommended Action
      Management Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.

References
1 Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51. [PMID: 11410561]
2 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
3 Product Information. Brovana (arformoterol). Sepracor Inc, Marlborough, MA.